Thorsteinn Loftsson

This inventor holds 28 USPTO granted patents and 15 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Ophthalmic Drug Delivery. Top assignees: Oculis Operations Sarl, Key Pharmaceuticals, Inc., Lipid Pharmaceuticals Ehf.. Active years: 1988-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thorsteinn Loftsson. Retrieved from https://idiyas.com/inventor/thorsteinn-loftsson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 28 (Patent Applications = 15)

% Patents Active = 89.3

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 1.9

ph-index = 12

Forward Citations = 482(Granted Patents)

Location History:

Reykorviv, IS (1991)
Reykjavik, IS (1988 - 2024)

Company Filing History:

12 out of 12

Oculis Operations Sarl

patents

4 out of 54

Key Pharmaceuticals, Inc.

patents

3 out of 3

Lipid Pharmaceuticals Ehf.

University of Florida Research Foundation Inc.

patents

Years Active: 1988-2026

Loading Chart...

Areas of Expertise:

Ophthalmic Compositions

Cyclodextrin Complexes

Dexamethasone

Diabetic Retinopathy

Ocular Inflammation

Nanotechnology

Permeability Enhancers

Active Pharmaceutical Ingredients

Fatty Acids

Topical Drugs

Viral Infections

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12521448 - Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery (2026-01-13),

2. 12403148 - PH stabilized ophthalmic compositions (2025-09-02),

3. 12403147 - Treatment of ocular inflammation following ocular surgery (2025-09-02),

4. 12397002 - PH stabilized ophthalmic dexamethasone compositions (2025-08-26),

5. 12397001 - Treatment of ocular inflammation with ophthalmic compositions (2025-08-26),

6. 12397000 - Stabilized ophthalmic dexamethasone compositions (2025-08-26),

7. 12383565 - Treatment of diabetic retinopathy with ophthalmic compositions (2025-08-12),

8. 12233133 - Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery (2025-02-25),

9. 12097209 - Diabetic retinopathy treatment with stabilized dexamethasone (2024-09-24),

10. 12090162 - Treatment of diabetic retinopathy (2024-09-17),

11. 12090161 - Treatment of ocular inflammation (2024-09-17),

12. 12090160 - Stabilized dexamethasone compositions (2024-09-17),

13. 12064455 - Free fatty acids and methods of manufacture and use for treating coronavirus and other viral respiratory infections (2024-08-20),

14. 11491240 - Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery (2022-11-08),

15. 11135311 - Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery (2021-10-05),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I'm happy to help you with the requested article about inventor Thorsteinn Loftsson.

Title: Dr. Thorsteinn Loftsson: Revolutionizing Ophthalmic Drug Delivery in Reykjavik

Introduction: Dr. Thorsteinn Loftsson, an esteemed inventor based in Reykjavik, Iceland, is a visionary in the field of pharmaceuticals with a significant focus on ophthalmic drug delivery.

Latest Patents: Dr. Loftsson holds an impressive total of 15 patents, with his most recent groundbreaking invention focusing on the preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery. These compositions revolutionize ophthalmic treatments, offering a new level of efficiency and precision in drug delivery.

Career Highlights: Throughout his career, Dr. Loftsson has made remarkable contributions to the pharmaceutical industry. He has worked with renowned companies such as Key Pharmaceuticals, Inc., and Oculis Ehf, where his innovative ideas have shaped the landscape of ophthalmic drug delivery.

Collaborations: Dr. Loftsson has had the privilege of collaborating with esteemed professionals in the field, including Nicholas S. Bodor and Einar Stefansson. Together, they have further advanced the development of revolutionary pharmaceutical products.

Conclusion: Dr. Thorsteinn Loftsson's dedication to advancing ophthalmic drug delivery has significantly impacted the industry. His innovative approach and collaborative spirit set him apart as a true leader in the field, making him a driving force behind the future of pharmaceutical advancements.

Profile summary based on public USPTO records.